CRISPR/Cas9-Based Engineering of a Large & Modular Cassette into a Safe Harbor Site to Improve CAR-T Cell Therapy Efficacy & Safety
Time: 3:00 pm
day: Conference Day Two
Details:
- Discussing advantages of ArsenalBio’s targeted, non-viral engineering platform, CRISPR integration of transgene by electroporation (CITE)
- Identifying and characterizing on- and potential off-target integration sites
- Developing a robust and scalable electroporation-based manufacturing process for integrated circuit T (ICT) cells
